Effect of chromium administration in controlling blood sugar in diabetic patients

A survey effect of chromium picolinate on glycemic control in type 2 diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201009264817N1

Enrollment

Registered

2010-10-16

Start date

2010-05-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: chromium picolinate 200 microgram daily for 3 months. Intervention 2: Placebo once daily for 3 months.

Treatment - Drugs

Placebo

chromium picolinate 200 microgram daily for 3 months

Placebo once daily for 3 months

Eligibility

Sex/Gender

All

Age

30 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: type 2 diabetic patients with HbA1C>7% Exclusion criteria: renal, hepatic, or heart failure

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HbA1C. Timepoint: at first and 3 months later. Method of measurement: HPLC.;FBS. Timepoint: at first and 3 months later. Method of measurement: R-1000 device.	—

Secondary

Measure	Time frame
BMI. Timepoint: At first and 3 month later. Method of measurement: weight/height2.;Serum chromium level. Timepoint: at first and 3 months later. Method of measurement: Atomic absorption spectrophotometry.;Serum lipids. Timepoint: At first and 3 months later. Method of measurement: Direct LDL-Chol.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Sara Saffarian

Jundishapur University

sarasaffarian@ajums.ac.ir+98 61 1374 3013

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026